NeuroPhage Raises $6.4 Million to Support Pre-IND Development Efforts

NeuroPhage Pharmaceuticals just secured $6.4 million to support the pre-IND development of their lead drug candidate, NPT002, as well as to support the continued development of their “second-generation fusion protein” drug candidates. The funds were primarily contributed by Mérieux Développement, with additional contributions from Shire LLC and other undisclosed investors. Dr. Valérie Calenda, Partner at Mérieux Développement, said “We believe the company’s transformative approach to addressing protein misfolding could make a major contribution to achieving greatly improved treatments for these disabling conditions that affect millions of people worldwide.” NeuroPhage has previously reported positive preclinical results in animal models of Alzheimer’s disease and Parksinson’s disease and the mechanism of action of their drug seems to hold great promise for ALS as well.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail